Continuous Renal Replacement Therapy Market Size, Share, Industry, Forecast and Outlook (2026-2035)

Continuous Renal Replacement Therapy Market Size

The global Continuous Renal Replacement Therapy (CRRT) market was valued at approximately USD 1.76 billion in 2025 and is projected to reach USD 3.66 billion by 2035, expanding at a CAGR of 8.8% during the forecast period 2026–2035. The market is gaining momentum as the rising incidence of acute kidney injury, chronic kidney disease, sepsis, and multiple organ failure increases demand for continuous renal support in critical care settings. Growing adoption of CRRT in intensive care units, combined with advances in automated treatment systems, filtration technologies, monitoring capabilities, and patient-specific renal support, is further supporting market expansion.

The competitive opportunity is increasingly focused on advanced CRRT systems, improved treatment efficiency, automation, and enhanced patient monitoring. Technological developments are enabling more precise fluid management and continuous renal support for critically ill patients, while increasing critical-care infrastructure and healthcare expenditure are supporting adoption across hospitals. The market is therefore shifting toward automated and integrated CRRT platforms, improved filtration and monitoring technologies, personalized renal support, and more efficient critical-care treatment, supporting sustained growth in the global Continuous Renal Replacement Therapy Market through 2035.

Continuous Renal Replacement Therapy (CRRT) is a medical therapy used to manage acute kidney injury and severe kidney dysfunction in critically ill patients. Unlike traditional intermittent hemodialysis, CRRT is a continuous process that operates over an extended period, typically 24 hours a day, providing gradual removal of fluid, electrolytes and waste products from the blood.

CRRT is primarily utilized in intensive care units (ICUs) for patients who are hemodynamically unstable or unable to tolerate the rapid fluid and solute shifts associated with intermittent hemodialysis. It offers a gentler approach to renal replacement therapy, allowing for more gradual correction of fluid and electrolyte imbalances while minimizing hemodynamic instability. 

The CRRT process involves the continuous circulation of the patient's blood through a specialized extracorporeal circuit that includes a hemofilter or dialyzer. Blood flows from the patient through vascular access, usually achieved through a central venous catheter into the CRRT machine where it passes through the filter or dialyzer. Here, excess fluid, electrolytes and waste products are removed from the blood, while essential solutes are maintained or supplemented as needed. The filtered or dialyzed blood is then returned to the patient, completing the circuit.

Continuous Renal Replacement Therapy Market Scope

  To know more insights Download Sample

Continuous Renal Replacement Therapy Market Dynamics

Drivers

Rising advancements in continuous renal replacement therapy machines

The rising advancements in continuous renal replacement therapy machines are expected to drive the market over the forecast period. Advancements in CRRT machine technology lead to improved efficiency in fluid and solute removal by allowing for more effective treatment of patients with acute kidney injury and other renal conditions. Enhanced performance translates to better patient outcomes and reduced treatment times, thereby driving market demand.

For instance, on May 25, 2021, Baxter International Inc. launched PrisMax 2, the latest version of the company’s next-generation platform. PrisMax 2 is designed to help simplify the delivery of continuous renal replacement therapy (CRRT) while providing hospitals the flexibility to meet the unique demands of the intensive care unit (ICU). PrisMax 2 will soon be available in more than 20 countries across the United States and Europe. 

Additionally, on Dec. 8, 2020, Medtronic plc launched the Carpediem Cardio-Renal Pediatric Dialysis Emergency Machine followed by U.S. Food and Drug Administration's (FDA) marketing authorization, the first Carpediem systems in the United States were successfully installed and are in use at Cincinnati Children's Hospital Medical Center. The first-of-its-kind Carpediem system is indicated for use in acute kidney injury or fluid-overloaded patients requiring hemodialysis or hemofiltration therapy. It is intended to provide continuous renal replacement therapy (CRRT) to patients weighing between 2.5 and 10 kilograms.

Advancements in CRRT machine design have led to the development of more compact and portable models. These portable CRRT machines offer greater flexibility in deployment, allowing for use in various clinical settings, including ICUs, ambulatory care units and even home settings. The increased accessibility and versatility of portable CRRT machines contribute to market expansion.

Due to the various advantages offered by CRRT machines, many manufacturing companies and institutes are focussing on developing these machines. For instance, on March 14, 2024, On World Kidney Day, Travancore Medicity unveiled Kollam’s inaugural Continuous Renal Replacement Therapy (CRRT) machine, marking a significant milestone in the healthcare journey. In critically ill kidney patients, the CRRT machine helps to control blood pressure, maintain fluid balance in the body and improve the chances of survival. 

Further, the increasing prevalence of renal injuries, rising aging population, increasing awareness about the CRRT and advancements in the development of novel products for the CRRT procedure are the factors expected to drive the market over the forecast period.

Restraints

Factors such as the high cost associated with CRRT machines, systems and consumables, risks and complications associated with the CPPT therapy and availability of alternative dialysis methods are the factors expected to hamper the market. 

Continuous Renal Replacement Therapy Market Segment Analysis

The global continuous renal replacement therapy market is segmented based on product type, modality, end-user and region.

The CRRT machines and systems segment accounted for approximately 43.7% of the continuous renal replacement therapy market share

The CRRT machines and systems segment is expected to hold the largest market share over the forecast period. Each CRRT modality, such as Continuous Venovenous Hemofiltration, Continuous Venovenous Hemodialysis and Continuous Venovenous Hemodiafiltration, offers unique mechanisms for solute clearance and fluid removal. Clinicians can select the most appropriate modality based on the patient's clinical condition, fluid status, metabolic needs and hemodynamic stability, allowing for personalized treatment approaches.

For instance, on August 3, 2023, Quanta Dialysis Technologies received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication of the Quanta Dialysis System, a compact and easy-to-use hemodialysis device for two modalities of continuous renal replacement therapy (CRRT): continuous venovenous hemodialysis (CVVHD) and slow continuous ultrafiltration (SCUF). Under the new 510(k), the Quanta Dialysis System is the only dialysis device FDA-cleared to provide intermittent hemodialysis (IHD), sustained low-efficiency dialysis (SLED) or bagless CRRT which creates dialysate on demand all in a single machine.

CRRT machines provide continuous renal support over extended periods, typically 24 hours a day, ensuring sustained removal of uremic toxins, electrolytes, and excess fluid. This continuous clearance offers more effective control of fluid overload, metabolic imbalances and uremia, leading to improved patient outcomes compared to intermittent therapies. CRRT machines and systems are designed for use in intensive care unit (ICU) settings, where critically ill patients require close monitoring and complex renal support. These systems are equipped with features such as integration with patient monitors, alarms for early detection of complications and compatibility with ICU equipment by facilitating seamless integration into the clinical workflow.

Continuous Renal Replacement Therapy Market Geographical Share

North America accounted for approximately 41.6% of the market share 

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and well-established healthcare infrastructure. North America especially the United States is a well-known hub for its strong presence of major players such as pharmaceutical companies and medical device companies. This presence of major players in the region expands the continuous renal replacement therapy market by focusing on the development of various CRRT accessories and other CRRT products in the market.

For instance, on April 05, 2022, Baxter International Inc. cleared the U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ST Set used in continuous renal replacement therapy (CRRT). The ST Set is a pre-connected, disposable, extracorporeal (outside the body) circuit that provides blood purification through a semipermeable membrane to be used with the PrisMax or Prismaflex control units (monitors).

Additionally, the region especially the United States boasts a highly developed healthcare infrastructure, with well-equipped hospitals, advanced medical technologies and a skilled workforce. This infrastructure supports the widespread adoption and utilization of CRRT machines and systems in clinical practice.

For instance, on January 27, 2023, for critically ill patients who can no longer undergo traditional dialysis, Peconic Bay Medical Center now offers a solution. The hospital announced it now offers continuous renal replacement therapy (CRRT), a blood purification process much slower than typical dialysis, for patients experiencing a kidney injury. While a patient may undergo standard dialysis a few hours a day, CRRT runs 24 hours a day. The much slower method is also more comfortable and gentler on the body.

Continuous Renal Replacement Therapy Market Competitive Landscape

The major global players in the continuous renal replacement therapy market include Baxter International Inc., Asahi Kasei Corporation, B. Braun Medical Inc., Medtronic plc, Fresenius Medical Care AG, NxStage Medical, Inc., Infomed SA, Medica SPA, Medites Pharma spol. s.r.o. and Quanta Dialysis Technologies Inc. among others. 

Continuous Renal Replacement Therapy Market Segmentation Analysis

By Product Type

• Consumables
  • Filters
  • Replacement Fluids
  • Others
• CRRT Machines and Systems
• Accessories
  • Catheters
  • Connectors
  • Monitors
  • Others 

By Modality

• Continuous Venovenous Hemofiltration (CVVH)
• Continuous Venovenous Hemodialysis (CVVHD)
• Continuous Venovenous Hemodiafiltration (CVVHDF)

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Homecare Settings
• Others 

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Report Benefits

The Continuous Renal Replacement Therapy Market report supports manufacturers in assessing product opportunities, technology direction, competitive positioning, and regional expansion priorities. Investors can evaluate market growth, leading product categories, regional opportunities, and vendor strategies.

For suppliers and technology companies, the analysis provides visibility into the CRRT ecosystem, including machines, systems, consumables, accessories, modalities, and end-user requirements. Procurement teams can use the findings to evaluate market trends, product developments, supplier positioning, and the factors influencing CRRT equipment adoption.

The report also supports strategy teams by bringing together market sizing, segmentation, regional analysis, competitive landscape assessment, product developments, regulatory developments, pricing considerations, supply-chain analysis, and growth strategies.

Target Audience

The market analysis is relevant to:

• CRRT machine and system manufacturers
• Renal-care equipment and consumable suppliers
• Medical device companies
• Hospital procurement and purchasing teams
• ICU and critical-care technology providers
• Healthcare investors and investment banking professionals
• Pharmaceutical and medical technology companies
• Emerging CRRT technology companies
• Healthcare strategy and business development teams
• Research professionals and market intelligence teams

Conclusion: Strategic Outlook Through 2035

The Continuous Renal Replacement Therapy Market presents a substantial opportunity for companies serving critical-care renal support. With a 2025 market size of USD 1.76 billion and a source-projected 2035 value of USD 3.66 billion, the market provides a clear long-term growth pathway at a CAGR of 8.8%.

The commercial case is supported by demand for renal support among critically ill patients, increasing adoption of CRRT in ICUs, technological improvements in machines and filtration systems, and investment in healthcare infrastructure. The 43.7% share held by CRRT machines and systems highlights the importance of core treatment platforms, while North America's 41.6% share demonstrates the value of mature healthcare infrastructure and established suppliers.

At the same time, cost, clinical complexity, treatment risks, consumable requirements, and competing dialysis approaches will continue to influence adoption. Vendors that combine treatment flexibility with practical ICU usability, monitoring capabilities, specialized applications, and reliable supporting consumables will be better positioned to compete.

For buyers and investors, the key consideration is not simply the growth of CRRT equipment demand. The more important question is how hospitals will allocate capital across integrated renal-support platforms as critical-care requirements become more complex. Tracking product clearances, hospital adoption, modality expansion, regional infrastructure investment, and supplier strategies through 2035 can therefore provide an important basis for procurement, investment, and market-entry decisions.